BRIEF-Atyr Pharma Announces Scheduling Of FDA Type C Meeting To Discuss Efzofitimod Program In Pulmonary Sarcoidosis
Reuters
Feb 03
BRIEF-Atyr Pharma Announces Scheduling Of FDA Type C Meeting To Discuss Efzofitimod Program In Pulmonary Sarcoidosis
Feb 3 (Reuters) - aTyr Pharma Inc ATYR.O:
ATYR PHARMA ANNOUNCES SCHEDULING OF FDA TYPE C MEETING TO DISCUSS EFZOFITIMOD PROGRAM IN PULMONARY SARCOIDOSIS
ATYR PHARMA INC - TYPE C MEETING SCHEDULED FOR MID-APRIL 2026
Source text: ID:nGNX32WNDX
Further company coverage: ATYR.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.